Financials BioRegenx, Inc.

Equities

BRGX

US31772N1000

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 07:39:20 03/07/2024 pm IST 5-day change 1st Jan Change
0.04 USD -4.65% Intraday chart for BioRegenx, Inc. +90.48% +78.51%

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 7.787 3.988 2.437 0.0222
EBITDA - -3.252 -1.882 -0.1049
EBIT 1 -0.5623 -3.253 -1.886 -0.1097
Operating Margin -7.22% -81.57% -77.4% -493.02%
Earnings before Tax (EBT) 1 -0.7817 -4.72 -2.224 -0.5712
Net income 1 -0.7817 -4.72 -2.224 -0.5712
Net margin -10.04% -118.37% -91.26% -2,567.87%
EPS 2 -0.0224 -0.1338 -0.0587 -0.002066
Free Cash Flow - -2.371 -1.251 -
FCF margin - -59.46% -51.31% -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 23/02/23 23/02/23 03/01/24 12/04/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 0.68 2.62 1.01 0.23
Net Cash position 1 - - - -
Leverage (Debt/EBITDA) - -0.8069 x -0.5363 x -2.149 x
Free Cash Flow - -2.37 -1.25 -
ROE (net income / shareholders' equity) - 179% 88% 270%
ROA (Net income/ Total Assets) - -107% -66.4% -151%
Assets 1 - 4.413 3.351 0.3783
Book Value Per Share 2 -0.0600 -0.0900 -0.0500 -0
Cash Flow per Share 2 0.0200 0.0200 0.0200 -
Capex - 0.03 - -
Capex / Sales - 0.79% - -
Announcement Date 23/02/23 23/02/23 03/01/24 12/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. BRGX Stock
  4. Financials BioRegenx, Inc.